α2,6-linked sialic acid receptor (SAα2,6Gal)

α2,6-linked sialic acid receptors are terminal glycan structures where N-acetylneuraminic acid (Neu5Ac) is linked to a galactose residue via an α2,6-glycosidic bond (nih.gov). These receptors are predominantly expressed in the human upper respiratory tract and serve as the primary attachment point for human-adapted influenza A and B viruses (nih.gov, dovepress.com). Beyond virology, these sialoglycans play critical roles in cell signaling by modulating the binding of galectins and Siglecs, thereby influencing processes like apoptosis and immune cell activation (nih.gov). In oncology, the overexpression of α2,6-sialylated glycans, often driven by the ST6Gal-I enzyme, is associated with tumor progression and resistance to therapy (nih.gov). Therapeutic strategies targeting these receptors include the use of sialidases like DAS181 to enzymatically remove the glycans, preventing viral entry and potentially sensitizing cancer cells to treatment (nih.gov). The specificity of these receptors for human-adapted viruses represents a significant biological barrier against the transmission of avian influenza, which typically prefers α2,3-linked sialic acids (aspariaglycomics.com). Monitoring the expression of these receptors using lectins like Sambucus nigra (SNA) is a common practice in both infectious disease research and diagnostic pathology (nih.gov).

Other names

Neu5Acα2,6GalHuman-type influenza receptor6'-sialyl-N-acetyllactosamine6'-SLNα2,6-sialoglycanSiaα2,6Gal

Enzymatic cleavage of terminal sialic acid residues from host cell surfaces to prevent viral attachment and entry.